Langabeer, S. (2023) “Suboptimal molecular response to tyrosine kinase inhibition associated with acquisition of a T240A ABL1 kinase domain mutation in a patient with chronic myeloid leukemia”, Experimental Oncology, 41(1), pp. 82–83. doi: 10.32471/exp-oncology.2312-8852.vol-41-no-1.12685.